Antibacterial wound dressing based on advanced nanotechnology to improve the efficiency of wound care

Infected wounds are a major cause of limb amputations among patients with chronic diseases like diabetes. 10mln amputations occur annually causing €100bln additional healthcare costs.

During COVID-19 pandemic the number of amputations rose 10 fold due to low efficacy of current solutions.Nanordica develops an advanced Antibacterial Wound Dressing (AWD) to prevent and treat wound infections. We have demonstrated that our AWD removes bacterial infection 8x better than current best.

Our value propositions are high efficacy and low cost.Global antibacterial wound dressing market is projected to reach €4.2bln in 2026 at CAGR 5.7%. Our business model is B2B using distributors to reach our customers, i.e. hospitals.

We have a priority for intellectual property and initiated a pilot clinical trial at the largest Estonian hospital.Our mission is to bring AWD to the market to improve the outcome of wound infections, lower healthcare costs and help hundreds of millions of patients.